Johnson & Johnson (NYSE:JNJ) Position Increased by Sawyer & Company Inc

Posted by Defense World Staff on Sep 25th, 2023

Sawyer & Company Inc boosted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,912 shares of the company’s stock after buying an additional 270 shares during the period. Johnson & Johnson accounts for approximately 2.0% of Sawyer & Company Inc’s investment portfolio, making the stock its 13th largest holding. Sawyer & Company Inc’s holdings in Johnson & Johnson were worth $4,289,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Atlantic Private Wealth LLC bought a new position in shares of Johnson & Johnson in the first quarter worth $32,000. GW&K Investment Management LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at about $35,000. Dark Forest Capital Management LP raised its position in shares of Johnson & Johnson by 1,044.4% during the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $42,000. Finally, Kepos Capital LP bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $45,000. 68.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Citigroup started coverage on Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price for the company. Stifel Nicolaus lifted their target price on Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Atlantic Securities boosted their target price on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $170.65.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Price Performance

NYSE JNJ opened at $160.50 on Monday. The company has a 50 day simple moving average of $166.51 and a 200-day simple moving average of $162.06. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The firm has a market capitalization of $417.13 billion, a price-to-earnings ratio of 32.49, a price-to-earnings-growth ratio of 3.25 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same quarter last year, the business posted $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.97%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.

Insider Activity

In related news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.